Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Long-Term Investments (2016 - 2022)

Historic Long-Term Investments for Assembly Biosciences (ASMB) over the last 6 years, with Q4 2022 value amounting to $18.6 million.

  • Assembly Biosciences' Long-Term Investments fell 3351.57% to $18.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.6 million, marking a year-over-year decrease of 3351.57%. This contributed to the annual value of $18.6 million for FY2022, which is 3351.57% down from last year.
  • Per Assembly Biosciences' latest filing, its Long-Term Investments stood at $18.6 million for Q4 2022, which was down 3351.57% from $11.9 million recorded in Q2 2022.
  • Assembly Biosciences' 5-year Long-Term Investments high stood at $28.0 million for Q4 2021, and its period low was $2.2 million during Q2 2018.
  • Moreover, its 3-year median value for Long-Term Investments was $15.3 million (2022), whereas its average is $15.6 million.
  • In the last 5 years, Assembly Biosciences' Long-Term Investments plummeted by 2674.58% in 2018 and then tumbled by 3351.57% in 2022.
  • Assembly Biosciences' Long-Term Investments (Quarter) stood at $2.2 million in 2018, then surged by 1169.09% to $28.0 million in 2021, then tumbled by 33.52% to $18.6 million in 2022.
  • Its last three reported values are $18.6 million in Q4 2022, $11.9 million for Q2 2022, and $23.5 million during Q1 2022.